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Abstract 
This paper aims to give a brief overview 
on traumatic brain injuries’ (TBIs) main 
pathophysiological mechanisms, to 
summarize the current available therapeutic 
strategies and offer a glimpse at possible 
future advancements in the field.  
The impact of TBI on health care 
systems and society is tremedous. While the 
surgical and intensive care management are 
relatively well standardized for acute TBI, 
subsequent, therapeutic interventions 
remain at the physician’s choice/ 
professional skills, and their clinical utility 
is still questionable.  
Previous experience and numerous trials 
have failed to demonstrate a consistent 
benefit from therapies like corticosteroids, 
lazaroids, nsaids vasodilators, glutamate 
blockers, immune modulators, or general 
hypothermia. 
 Novel achievements in neuroprotection 
are now expected from developing anti-
apoptotic agents (such as caspase and/or 
calpain inhibitors), from more potent 
antioxidants, cholinergic agents, alpha 
blockers from researching various 
physiologic substances, like melatonin, 
protirelin, inosine, progesterone, and 
including from regenerative medicine and 
physiatric, assisstive technology/  
bioengineering advancements. 
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Introduction 
In head traumas, the primary brain 
damage occurs at the time of initial impact, 
and is refractory to most prophylactic/ 
therapeutic actual strategies. The secondary 
injuries’ ”cascade” is the result of complex 
(quite similar in traumatic injuries of the 
central nervous system (CNS), i.e. both, 
the brain and the spinal cord; they have 
been detailed, in some of our previous 
articles, so we shall not further develp them 
here) pathophysiological events that unreel 
over a longer period of time and are, at least 
in theory and partially, preventable and 
treatable.  
The main physical mechanisms of the 
primary brain injuries are:  
• Direct impact/ physical contact with 
the under-skull tissue: penetrating head 
injuries - the dura is pierced (bullet or knife 
wounds to the head are such examples).  
• Indirect impact/ physical contact with 
the under-skull tissue: closed head injuries. 
Closed or blunt head injuries represent the 
majority of cases in civilians; many of these 
injuries are produced by motion without 
impact and/ or external evidence of injury 
to the head. The most common causes are 
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sudden acceleration or deceleration. The 
dura remains intact. 
The physical factors influencing – 
mainly through inertial and/ or contact 
forces – the type and severity of a closed 
injury to the brain, include energy load per 
unit area, duration, velocity and direction of 
the force, configuration of various parts of 
skull, rate of acceleration or deceleration, 
and diffusion of forces resulting in agitation 
of the entire cerebrum. 
More precisely, three principal physical 
mechanisms are described: impact loading 
(percussion of the head with a solid object, 
at a significant speed - may involve coup 
and contrecoup injuries, if the moving head 
hits a fixed object), impulsive loading 
(abrupt motion/ cessation of motion of the 
head, without significant contact with other 
objects) and static or quasistatic loading 
(external forces applied gradually – 
therefore the importance of the impact 
velocity is not always determinant – with a 
crushing effect; it is a rare occurrence). (21, 
37) 
As a bottom line it is stated that the 
amount of brain damage is proportional to 
the rotational acceleration achieved and the 
mass of the brain, because contact and/or 
inertial forces may strain the brain tissue – 
i.e. the amount of its deformation - beyond 
its structural tolerance, thus leading to 
injury.  
There are described three basic types of 
tissue deformation: by compression 
(compressive), by tissue stretching (tensile) 
and by tissue distortion, when sliding over 
other tissue/s (shearing) (21, 37). 
Considering the aspects described above, 
primary brain injuries can be classified as 
focal injuries (penetrating wounds - with 
skull fractures -, intracranial hemorrhages, 
lacerations, contusions, multiple possible 
trauma at auditory-vestibular level – in 
striking of the temporal region) or diffuse 
ones (diffuse axonal injuries – DAI, 
including a form considerate mild: 
concussions)(21, 37) 
The major lesional / pathophysiological 
conditions involved in the secondary brain 
damages are currently considered to be 
(94): 
• brain tissue swelling  
• hemorrhage (extradural, subdural, 
subarachnoid, intracerebral, intraventri-
cular) 
• loss of the local/ regional blood flow – 
generating ischemia 
• (and possibly/ added) infection 
They correspond, at cellular and 
subcellular level, to (what modern research 
has identified as a cascade of intimate events 
leading, in vicious circles, to the secondary 
injury): failure of cellular energy 
metabolism, local intense generation of 
reactive oxygen species/ oxidative stress 
(folowed by biological membranes’ lipid 
peroxidation, DNA and proteins damage/ 
misfolding), immune shifts/ inflammatory 
processes/ acidosis, global and/or focal 
multifactorial ischaemia, ischemic 
penumbra and alteration of regional micro-
circulation, ionic disturbances (leading to 
cells swelling including massive edema – 
followed, because of suddenly installed 
osmolysis – by cell induced necrosis/ 
passively dying off), excitotoxicity (excess of 
neurotransmitters – especially glutamate – 
and also enhanced intracellular influx of 
calcium ions) and related activation of 
apoptotic genes and thus of different 
pathways of “delayed mechanisms of cell 
death”: apoptosis and apoptosis-like 
processes (60, 94).  
Hence, the secondary events’ ”cascade” 
entails an extremely complex and extended 
 
 
 
Romanian Neurosurgery (2011) XVIII 1: 11 – 30          13 
 
 
 
reaction, practically of the entire body: from 
its gene level to the ”macroscopic”/ clinical, 
one. 
Therefore, the concept of secondary 
brain injuries has become the basis – many 
of them being inmtimate targets – for 
developing an array of neuroprotective 
modern therapies. 
Neuroprotective therapies 
Below we give an extensive list of 
potential neuroprotective therapies, 
classified by mechanism of action and 
clinical use. This classification paradigm 
also appeared in one of our previous papers, 
dedicated to neuroprotection in spinal cord 
injury (SCI), published in 2009, the 
October issue of Spinal Cord journal. 
We will further discuss some of these 
therapeutic drugs and procedures. Our 
color code serves to achieve a balanced, 
selective approach; the present paper refers 
to the drugs effective/ researched in TBI 
and to some equally effective/ researched in 
both TBI and SCIs; considering both 
conciseness and a selective review of recent 
and/or less discussed matters, not all items 
will be elaborated: 
Colour code: 
• Mainly used/researched for brain 
injuries 
• Rather equal efficiency in SCI and 
TBI 
• Mainly used/researched for spinal 
cord injuries 
 “Classical” drugs, with a long history 
of clinical use 
• Peptide mixtures with neurotrophic 
actions (Cerebrolysin®, 
Actovegin®) 
• Musculotropic vasodilators 
• Nootropic agents 
• Anesthetic agents (including Xenon 
gas, with anti-excitotoxic properties) 
• (Other) Hormones 
• Sex hormones (progesterone) 
• TRH (thyrotropin-releasing 
hormone) and analogues 
• Anti-inflammatory drugs and 
immune modulators: 
• SAIDs (Methylprednisolne) 
• Lazaroids (21-aminosteroids) 
• NSAIDs (COX2 inhibitors) 
• IL 10 (Interleukin 10) 
• Glatiramer acetate (Copaxone®) 
• Anti-excitotoxic agents (glutamate 
blockers) 
• Xenon gas 
• NMDA blockers 
• AMPA blockers 
• KDI tripeptide 
• Iron kelators (deferoxamine, 2,2’-
bipyridine, quercetin) 
• Vitamins and other nutritional 
supplements (B vitamins, tioctic acid, 
selenium, zinc, magnesium, etc.) 
• Ca2+ channel antagonists 
(nimodipine) 
• Lithium 
• Statins (Simvastatin) – acting as 
antagonists of growth inhibitory 
signals in central nervous system  
• Dopamine agonists: 
• Bromocriptine 
• Lisurid  
• Cholinergic agents 
• Citicoline 
• Rivastigmine (Exelon) 
New / experimental drugs 
• KDI tripeptide 
• Monosialoganglioside GM 1 
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• IGF-1(Insulin-like Growth Factor) 
• Neurotrophins – characterized by 
pleiotropic effects 
• GDNF (Glial Derived 
Neurotrophic Factor) 
• BDNF (Brain Derived 
Neurotrophic Factor) 
• NGF (Nerve Growth Factor) 
• NT-3 (Neurotrophin-3) 
• CNTF (Cliary Neurotrophic 
Factor) 
• Apoptosis inhibitors 
• Protease inhibitors (caspase 
inhibitors, calpain inhibitors) 
• PARP (poly(ADP-ribose) 
polymerase) inhibitors 
• DMSO (dimethyl sulfoxide) 
• Antioxidants  
• Glutamate transporters (EAAC1 
protein) 
• Free radical scavangers: ascorbate, 
vitamin E, beta-carotene, alpha-
tocopherol, penicillamine, 
superoxide dismutase, Q10 
coenzime 
• L-cysteine 
• Selenium, zinc, magnesium 
• Cell adhesion molecules (L1-CAM) 
• Erythropoietin 
• Melatonin 
• Inosine (Axosine™) 
• AIT-082 (leteprinim potassium, 
Neotrofin) 
• 4-aminopyridine (Fampridine) 
• Riluzole 
• Antogonists of the growth inhibitory 
signals in CNS 
• Monoclonal antibodies to Nogo 
• Phosphodiesterase inhibitors 
(Rolipram) 
• Dibuthyril cyclic AMP (db 
cAMP) 
• Inhibitors of Rho signaling (Cethrin) 
• Scar preventing substances 
(chondroitinase, cordaneurin, EphA4 
antagonists) 
New / experimental procedures 
• Local hypotermia 
• Combinatory (‘COMBO’) strategies 
• Hyperbaric oxygen therapy 
• Fusion technology (Polyethylene 
glycol) 
• Physical therapy 
• Low-level LASER therapy 
• Oscillating field stimulator (OFS) 
• Functional electrical stimulation 
• Immunetherapy with activated 
macrophages or lymfocytes 
Pharmacological and physiatric 
stimulation of the spinal central pattern 
generator (CPG) 
Neurotrophic peptide mixtures 
Cerebrolysin 
Cerebrolysin is a mixture containing 
85% free amino acids and 15% biologically 
active low-molecular weight petides, 
prepared by enzymatic lysis of lipid-free pig 
brain products. Its exact mechanisms of 
action are not known, but the drug has 
been proven useful in a large number of 
conditions, including neurological trauma 
of any type (3, 108), stroke (48), 
Alzheimer’s and other degenerative 
disorders of the brain. The most numerous 
clinical studies with Cerebrolysin® were 
conducted in patients with dementia 
(Alzheimer’s and vascular) and they yelded 
good results, with significant improvement 
of cognition in the treated subjects (35). To 
date, there are no reported significant 
adverse reactions to Cerebrolysin®, except 
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for allergies and seldom CNS excitability 
enhancements. 
The small molecules contained by the 
mixture readily cross the blood-brain 
barrier. They exert neuroprotective, 
neuroptrophic, nootropic and 
neuromodulating – i.e. multimodal – effects 
on the CNS, similar to those of the 
naturally occuring growth factors, especially 
the Nerve Growth Factor. Many 
experimental studies (67, 74, 82) and 
clinical trials (3, 48, 108) suggested a variety 
 
of mechanisms for these beneficial effects: 
• An increase in the efficiency of the 
aerobic neuronal metabolism 
• Stimulation of protein synthesis in the 
CNS 
• Stimulation of neuronal differentiation 
• Inhibition of reactive oxygen species 
formation 
• Inhibiton of lipid peroxidation (67) 
• Anti-excitotoxic actions (74) 
• Anti-apoptotic effects (32) 
• Immunoactive properties (84) 
 
Figure  1 Correspondence between Cerebrolysin’s main effects and pathways of the secondary injuries cascade 
it targets/ counteracts: pleiotropic, but by stimulating neuro-/ synaptogenesis and respectively, neuroplasticty, it 
results in a multimodal way of action, too (G. Onose et al. Neuroprotective and consequent neurorehabilitative clinical 
outcomes, in patients treated with the pleiotropic drug cerebrolysin, Journal of Medicine and Life, 2(4): 350-61, 2009) 
 
Actovegin  
Actovegin is a deproteinized 
hemoderivative of calf blood, obtained by 
ultrafiltration. It contains electrolytes, 
essential trace elements and 30% organic 
components: amino acids, oligopeptides, 
nucleosides, inositol phospho-
oligosaccharides (IPOs), intermediary 
products of the carbohydrate and of the 
lipid metabolism, and components of the 
cellular membranes, such as 
glycosphingolipids. The molecular weight 
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of the organic components is below 6000 
Da. 
The main effect of Actovegin® is to 
increase the cellular energy metabolism, by 
increasing the respiratory capacity of 
mitochondria, the oxygen and the glucose 
uptake. Also, the IPO fraction of 
Actovegin® demonstrated a positive effect 
on glucose carrier activity (GLUT1): it 
stimulates glucose uptake by the cerebral 
tissues, as well as other tissues and activated 
glucose oxidation. The IPO fraction acts 
indirectly on the citric acid cycle, by 
increasing acetyl coenzyme A synthesis(12). 
Several small clinical studies found 
benefits of Actovegin® administration in 
elderly patients with organic brain 
syndrome(45), in dyscirculatory 
encephalopathy(55, 100) and in TBIs, 
where the investigators found some positive 
effects of the drug on the EEG changes(92). 
Actovegin® is very well tolerated, and few 
adverse reactions have been described; 
allergies are the most frequent side effects 
and severe anaphylaxis has been reported in 
one case(56). 
Musculotropic asodilators 
Papaverine  
Cerebral vasospasm is a severe 
complication that can develop in 5% to 50% 
of patients with TBI(97), especially in 
relation to subarachnoid hemorrhage 
(SAH) or other intracranial hemorrhages. 
The posttraumatic cerebral vasospasm can 
lead to massive stroke, increasing the 
morbidity and the mortality after head 
injuries, which is why treating it is one of 
the main neuroprotective measures in these 
patients. 
Papaverine (an opium alkaloid) is a 
potent smooth muscle relaxant, but 
hypotension limits its systemic application. 
It has been used in topical (with a syringe, 
gelfoam, cotton pledgets, or controlled-
release drug pellets) application on arteries 
during surgery(85). Local application in a 
controlled-release matrix has been clinically 
tested in a study involving 117 patients. The 
results showed that the procedure 
effectively prevented the development of 
symptomatic vasospasm and improved 
neurological outcome in treated patients, 
with no adverse effects(17).  
It has also been administered as intra-
arterial injections, but the effectiveness of 
this method in reversing vasospasm-
associated cerebral hypoperfusion is 
controversial. Some authors found it 
useful(52), but some found no beneficial 
effect of intra-arterial papaverine(96). Also, 
there is one case report of transient severe 
brain stem depression during intra-arterial 
papaverine(6). 
Vinpocetine (Cavinton) 
Vinpocetine is a synthetic derivative of 
vincamine, an alkaloid derived from vinca 
minor. It was discovered during the late 
1960s and has been used in the treatment of 
cerebrovascular and cognitive disorders for 
decades. Its primary mechanism of action is 
direct vasodilation of cerebral vessels, 
enhancing the cerebral blood flow, but 
hypotension is a rare side effect. It also 
reduces platelet aggregation (by inhibiting 
its capacity to take in adenosine), increases 
platelet plasticity and decreases blood 
viscosity. More recent studies suggested 
that vinpocetine and vincamine may 
decrease the mitochondrial disfunction 
induced by glutamate excitotoxicity (63, 22, 
93). In vitro and in vivo experiments 
demonstrated the the compound inhibits 
phosphodiesterase 1, blocks voltage-
operated calcium channels and voltage-
dependent natrium channels (13), and has 
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antioxidative action(68). A clinical trial with 
vinpocetine in newborns with intracranial 
birth trauma demonstrated that the 
compound inhibits posttraumatic epileptic 
activity (25). 
A small Hungarian clinical study showed 
that intravenous administration vinpocetine 
in stroke patients increases the cerebral 
blood flow and the glucose metabolism, 
especially in the thalamus and caudate 
nucleus(90). 
All this accumulating data suggests that 
intraveous vinpocetine might a useful 
therapeutic tool for head injury treatment, 
but further evidence is needed. 
Vincamine (Ceredia, Oxybral, Oxicebral, 
Cetal, Devincan, Pervincamin) appears to 
have the same pharmacological 
characteristics, except the risk of 
hypotension and cardiac arrhythmias is 
higher with intravenous administration.  
Clinical trials found orally administered 
vincamine beneficial in primary 
degenerative and vascular dementia, but 
there are no studies vincamine for CNS 
tauma. 
Ginkgo biloba extract (Tanakan) 
Ginkgo biloba is the best-selling 
phytomedicine on the European market. It 
has been widely used to treat a variety of 
conditions, including peripheral vascular 
disease, vertigo, ischemic heart diseases, eye 
diseases, depression, ischemic stroke, 
demetia and TBI. The extract contains 
flavone glycosides, ginkgolides, bilobalides 
and other constituents. Pharmacological 
effects include peripheral arterial dilation, 
free radical scavanging, inhibition of 
reactive oxygen species formation, 
inhibition of lipid peroxidation, activation 
of energy metabolism, decreasing platelet 
aggregation. 
In therapeutic doses, the side effects are 
mild: gastro-intestinal irritation, headache, 
allergic skin reations. Very large doses have 
been reported to cause diarrhea, nausea, 
vomiting and restlessness. A few case 
reports described spontaneous bleedings 
related to Ginkgo biloba. 
Experiments with Ginkgo biloba on rat 
models of TBI showed that the extract 
improved the behavioural outcome in the 
injured animals, and histology 
demonstrated that the treated rats 
developed less cerebral edema in response 
to injury (4). 
Nootropics 
Nootropic drugs form a large group of 
substances known to enhance cognitive 
abilities in cerebrovascular, involutive and 
post-traumatic disorders. Currently, they 
are successfuly used as part of the 
rehabilitation therapy for the patients with 
chronic TBIs. No significant adverse 
reactions have been reported. 
Pyritinol (Encephabol, Enerbol) 
The compound is chemically affined to 
pyridoxine and penicillamine. It facilitates 
the passing of glucose across the blood-
brain barrier and increases its metabolism 
in neuronal tissue; also has antioxidant 
properties (44). Pyritinol is successfuly used 
as an immune-enhancer in rheumatoid 
arthritis (50).  
It has been tested in small clinical studies 
for comatose patients (after head traumas). 
The results showed slightly improved 
neurological outcome and a significant 
decrease in mortality (18, 102). The drug is 
generally well tolerated; adverse reactions 
are more frequent with prolonged 
administration and high doses: agitation, 
insomnia, gastrointestinal symptoms, 
nausea, headache, and rarely allergies. A 
survey of six cases suggested a link between 
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pyritinol and severe cholestatic hepatitis 
(58); another rare side effect is acute 
pancreatitis (89). 
Racetams  
Piracetam (Pyracebral, Nootropil, 
Pyramen, Gabacet) is a cyclic derivative of 
GABA (gamma-aminobutyric acid). Its 
proposed mechanisms of action are: 
improvement of cross-hemispheric 
information transfer, stimulation of the 
cholinergic system (via muscarinic 
receptors), decrease of neuronal oxygen 
consumption, increase of glucose oxidation, 
with subsequent ATP formation. Clinical 
studies indicate a weak protective effect 
against hypoxia. 
Piracetam has been extensively studied 
for its beneficial effects in dyslexia 
(probably due to the enhancement of cross-
hemispheric communication). Yet, a recent 
clinical study found no significant 
improvements on speech disorders after 
ischemic stroke with prolonged (6 months), 
high doses of Piracetam (36). A Polish 
clinical trial, which included 100 patients, 
concluded that high doses of piracetam 
improved clinical outcome in head injury 
patients, if started immediately after the 
trauma (33). Still, a recent paper classifies 
Piracetam among the drugs detrimental for 
neuroprotection (40). 
Pramiracetam (Pramistar®) is a 
liposoluble racetam derivative. Recent 
clinical trials indicate that it might be the 
most potent nootropic substance. It 
accelerates the acethylcholine turnover by 
activating the HACU (High Affinity 
Choline Uptake) system and the nitric 
oxide-synthase, it inhibits the cerebral 
neuropetidase, it has antidepressant actions. 
Reports suggested that the drug improved 
cognition in TBI patients (57).  
Anaesthetic agents 
Anaesthetic agents are used during brain 
surgery or in head traumas refractory to 
conventional therapy. Some authors used 
them prophylactically, in an attempt to 
improve outcome in TBI patients. 
Anaesthetics make the object of another of 
our articles, and are only briefly discussed 
in the present paper. 
We will mention that of all the clinically 
available anaesthetics, the barbiturates seem 
to have the greatest neuroprotective 
potential (26). They reduce the functional 
activity of the brain, the cerebral metabolic 
rate of oxygen (CMRO2), therefore 
lowering the cerebral metabolic demands 
(94), the cerebral blood flow and the 
intracranial pressure (ICP). This results in 
an increase of global cerebral perfusion and 
oxygenation. 
There have been many published clinical 
trials with barbiturates in head injury 
patients, but none of them demonstrated 
that this therapy has significant benefits. 
Moreover, barbiturates were associated 
important complications, like hypotension, 
infection, hypothermia( 81) and severe 
hypokalaemia with rebound hyperkalaemia 
(62). 
In conclusion, analysis of currently 
available data on the use of barbiturates 
shows that they might be beneficial in 
selected, hemodynamically stable, patients 
with important, intractable elevations of 
ICP. 
Sex hormones 
The observation that female laboratory 
animals recover better than males after 
traumatic and ischemic brain injuries (5, 51, 
78) led to the hypothesis that progesterone 
and estrogens might have neuroprotective 
properties. Subsequent studies showed that 
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both estrogen and progesterone reduce the 
effects of TBI when administered to males 
or ovariectomized females (64). While 
estrogens were also shown to exacerbate the 
brain damage, especially in animal models 
of ischemic stroke (16, 38), progesterone 
had no significant side effects in preclinical 
studies. It could be given to both males and 
females, without affecting gender 
differentiation and sexual functions (88). 
Intensive research during the last decade 
demostrated that sex steroid hormones are 
up-regulated in the CNS following 
traumatic injuries (31) and exert an 
important neuroprotective and 
neuroregenerative effect. The mechanisms 
for these beneficial effects are complex, 
diverse and not completely understood.  
It has been demonstrated on animal 
models that progesterone markedly reduces 
edema after brain injury (16), modulates 
glial cell activity (31), decreases lipid 
peroxidation, reduces the expression of pro-
inflammatory genes, attenuates 
mitochondrial dysfunction (87), decreases 
pro-apoptotic and increases anti-apoptotic 
enzymes (24), enhances remyelination, 
synaptogenesis and dendritic arborization 
(75).  
A phase II randomized, double-blind, 
placebo-controlled clinical trial (called 
‘ProTECT’) was conducted at the Emory 
University, Atlanta, to test the effects and 
assess the safety of intravenous 
progesterone in acute TBI. The study 
enrolled 100 adults with blunt head injury. 
The progesterone administration was 
started within the first 11 hours of initial 
trauma and patients were re-assessed at 30 
days. The results of the study showed that 
no significant adverse effects were found, 
and progesterone reduced the 30-day 
mortality to less than half of the controls. In 
the treated group, the patients with 
moderate TBI had better functional scores, 
but those with severe head injury had 
longer duration of coma (109). Other small 
clinical studies gave encouraging results 
with the use of this hormone in both, male 
and female patients (86) and several phase 
II and III clinical studies are currently 
ongoing or recruiting, to study the effects of 
intravenously administered progesterone in 
acute TBI (42). 
TRH and analogs 
The tripeptide thyrorotropin-releasing 
hormone (TRH, protirelin) and some of its 
analogues have long been recognized as 
neuroprotective factors. Studies showed 
that TRH administration improves 
neurological outcome in animal models of 
CNS trauma (29, 99). Protirelin and its 
analogues seem to antagonize a variety of 
mechanisms that lead to the secondary 
damage in TBI: the opiate receptor 
activation by injury-induced endorphin 
release, the glutamate toxicity (99), the lipid 
peroxidation, the inflammatory cytokines. 
A major drawback for the clinical use of 
these compounds as neuroprotectives are 
their undesired endocrine, autonomic and 
analeptic effects. Also, TRH has a poor 
blood-brain barrier penetration and this 
raises the problem of the route of 
administration. 
A small clinical trial was conducted in 
California with intravenous TRH in 
patients with acute spinal cord injuries. 
They found no significant side effects; the 
treated group showed a better neurological 
outcome, but these results are difficult to 
interpret, given the small number of 
patients included in the study (72). There 
have been no clinical trials to test TRH in 
TBI. 
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Several analogues with better brain 
penetration and lesser endocrine effects 
have been synthesized, and some of them 
are currently under evaluation for possible 
entry into future trials (27, 28). 
Xenon gas 
Xenon is a naturally occuring gas that 
may prevent or ameliorate acute neuronal 
injury, as it seems to inhibit the activity of 
glutamate receptors (106). 
Brain damage, with neurocognitive 
deficit, is for instance, a potential 
postoperative-complication following 
coronary artery by-pass grafting (CABG). 
One study showed that xenon 
administration before CABG, while on 
hypothermic cardiopulmonary bypass, 
 
using both a standard anesthetic breathing 
circuit and the oxygenator had no harmful 
effects (53).  
Anti-excitocitotoxic agents 
The recognition of the role of excessive 
amounts of glutamate in the intracellular 
calcium accumulation in CNS lesions has 
opened an entirely new research field. The 
role of excitatory neurotransmitters in the 
progression of various neurologic disorders, 
including trauma, stroke, dementia, 
multiple sclerosis, epilepsy, glaucoma is 
attracting more and more attention (65). 
Currently, the glutamate-receptor 
antagonists are probably the most important 
issue in neuroprotection research. 
 
 
Figure 2 Schematic synthesis of the main effects of glutamate and, consequently, of its blockers. Legend: Ca2+ – 
calcium ions; NOS – nitric oxyde synthase; NO – nitric oxyde; PLA2 – phospholipase A2; ROS – reactive oxygen 
species; AA – arachidonic acid; LTs – leucotriens; PGF2α – prostaglandin F2α; TXA2 – tromboxane A2  
(G. Onose et al. Integrative emphases on intimate, intrinsic propensity/ pathological processes – causes of self recovery limits and 
also, subtle related targets for neuroprotection/ pleiotropicity/ multimodal actions, by accessible therapeutic approaches - in spinal 
cord injuries. Journal of Medicine and Life, 3(3): 262-74, 2010) 
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Glutamate has 4 types of receptors: 
NMDA (N-methyl-D-aspartic acid), 
AMPA (alpha-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid), kainic 
acid and the metabotropic receptors, linked 
to the G protein. A large number of 
glutamate receptors has been identified, and 
as a consequence, a huge variety of 
glutamate antagonists were developed and 
studied. 
Unfortunately, several clinical trials of 
glutamate antagonists failed to confirm the 
encouraging data from in vitro and in vivo 
studies. 
Selfotel (CGS19755), a competitive 
NMDA blocker, was the first glutamate 
antagonist that underwent phase III clinical 
trial in TBI, but the research project had to 
be shut down due to an increased mortality 
report from the simultaneously running 
stroke trials (7, 65). 
Dexanabinol (HU-211) is a cannabinoid 
and a non-competitive NMDA antagonist. 
It also acts as a free radical scavanger 
inflammatory cytokine inhibitor. In phase 
II trials, results showed if administered 
within 6 hours of injury, it reduced 
mortality, it lowered ICP and had no 
significant side effects. But the recently 
published results of o phase III multicentric 
clinical trial, involving 861 patients with 
severe TBI demonstrated that though it is 
safe, Dexanabinol has no therapeutic 
benefits in head injuries (54). 
Traxoprodil (CP-101,606) is a non-
competitive NMDA antagonist, highly 
selective for the NR2B subunit. Phase II 
clinical trials found it to be safe, but with no 
consistent therapeutic benefits. A phase III 
randomized, double-blind, placebo-
controlled trial tested the efficacy of a 72-
hour infusion of traxoprodil, started within 
8 hours of the initial brain injury. It 
provided no substantial evidence of the 
drug’s efficacy in TBI (115). Eliprodil also 
failed to show any therapeutic efficacy. 
Aptiganel (cerestat) another non-
competitive NMDA antagonist, entered a 
clinical trial, but the study was stopped 
following negative reports from the 
concurrently running ischemic stroke trial 
(65). 
D-CPP-ene (SDZ EAA-494) a 
competitive NMDA antagonist, failed to 
demonstrate any benefit in a phase III 
clinical trial.  
Xenon, an anaesthetic gas, has also been 
identified as a non-competitive NMDA 
receptor antagonist. Studies on neuronal 
cultures and lab animals demonstrated that 
it provides protection against hypoxia-
induced excitotoxicity (41, 69, 70). The 
advantage of xenon is its long history of 
clinical use (as an anaesthetic) which has 
proven it safe in humans. 
Nutritional supplements 
Magnesium is a non-competitive 
NMDA antagonist and it may exert 
neuroprotective actions through several 
other mechanisms: increased cerebral blood 
flow to ischemic areas, competitive 
antagonist at all voltage-sensitive calcium 
channels, amendament of cellular energy 
metabolism, enhanced mitochondrial 
calcium buffering.  
Studies on animal models of brain 
trauma showed that magnesium sulfate 
infusion, administered immediately after 
injury, significantly reduces the tissue loss 
and improves neurological outcome (14, 
39). 
A pilot clinical trial was conducted to test 
the safety and efficacy of field 
administration of intravenous magnesium 
sulfate in acute stroke patients (the FAST-
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MAG trial). The results were encouraging: 
magnesium significantly ameliorated 
recovery with no severe side effects (one 
patient with skin flushing) (80). Currently, 
the FAST-MAG trial is recruiting patients 
for phase III (42). 
Magnesium appears to be a promising 
neuroprotective tool in TBI, but further 
evaluation is needed. 
Ca2+ channel antagonists 
The proposed mechanisms of action for 
calcium-channel blockers in TBI are the 
reduction of the calcium cellular influx and 
the prophylaxis/ lysis of the cerebral 
vasospasm that may accompany acute 
traumas, especially when subarachnoid 
hemorrhage (SAH) is associated (7).  
Nimodipine (Nimotop) is dihydro-
pyridine calcium channel blocker. Since it 
has greater lipid solubility than the other 
similar compounds and consequently some 
selectivity for the cerebral vasculature, the 
drug is already established for the 
prevention and treatment of cerebral 
vasospasms. It is approved by FDA, in oral 
administration, for the therapy of cerebral 
ischemia following SAH (2, 23). 
The use of Nimodipine in unselected 
TBIs is however questionable, given the 
known side effects of calcium-channel 
blockers: systemic hypotension, cerebral 
vasodilation, decreased cerebrovascular 
reactivity. Large clinical studies, led by the 
Head Injury Trial Group (HIT I, II and III) 
were carried on in unselected TBI patients 
in Europe and they and they found some 
outcome improvements in injuries 
associated with traumatic SAH (61, 95).  
A review of six randomised controlled 
trials with Nimodipine in unselected 
patients with acute TBI concluded that the 
drug may only have some beneficial effects 
in selected subjects, with SAH, while being 
potentially harmful in other brain injuries 
(49). Another review, of four randomised 
controlled trials with Nimodipine for 
traumatic SAH, found no beneficial effects 
(98). 
Dopamine agonists 
Dopamine agonists are used as cortical 
stimulants, to treat a variety of neurological 
symptoms: aphasia, akinetic mutism, 
amotivational syndrome/ apathy/ abulia/ 
anergia, attention disorders, neglect, 
depression (34). Recent studies suggested 
that these compounds may also provide 
neuroprotection by inhibiting glutamate 
neurotoxicity (83). 
Bromocriptine, an ergot alkaloid is a 
potent agonist for D2 dopamine receptors 
and some serotonine receptors, currently 
used in the treatment of pituitary tumors 
(with hyperprolactinaemia or acromegaly), 
Parkinson's disease, neuroleptic malignant 
syndrome, and type 2 diabetes. It has been 
shown to interfere with the activity of 
astroglial glutamate transporter GLT-1 
(EAAT2) (83).  
Bromocriptine has been used with good 
clinical results in the paroxysmal autonomic 
instability with dystonia (PAID)/ 
“diencephalic seizures” – a syndrome 
consisting in tachicardia, tachipneea, 
hyperthermia, diaphoresis and decerebrate 
posturing, following severe TBIs (10, 15). 
Also, the administration of Bromocriptine 
to posttraumatic vegetative state and 
minimally conscious state patients led to 
improvements of the motor and cognitive 
outcomes (66). 
The most common side reactions of 
bromocriptine are: orthostatic hypotension, 
nausea, headaches and vomiting, liver 
toxicity (107). 
 
 
 
Romanian Neurosurgery (2011) XVIII 1: 11 – 30          23 
 
 
 
Cholinergic agents 
Cholinergic agents (Rivastigmine – 
Exelon) are currently used in the treatment 
of mild to moderate dementia in 
Alzheimer’s and Parkinson's diseases, with 
some beneficial results in cognitive 
functions. Their use is based on the 
hypothesis that the cholinergic system 
stimulates brain areas related to learning 
and memory. 
Citicoline – cytidine diphosphate-
choline (CDP-Choline) is an intermediate 
product in the generation of 
phosphatidylcholine from choline. It is sold 
in many countries as a psychostimulant/ 
nootropic dietary supplement. The 
presumed mechanisms for it’s 
neuroprotective effects include: 
counteracting excitotoxicity, maintaining 
cellular adenosine 5'-triphosphate levels, 
stimulating neuronal plasticity (43). It has 
been used for many types of cognitive 
impairment, especially of vascular and 
degenerative ethiology (30). A few small 
clinical studies reported significant 
improvements with the use of this 
compound (20), but larger trials are needed 
to establish the efficacy of Citicoline. 
Apoptosis inhibitors 
Traditionally, neuroprotective therapies 
have been mainly focused on reducing 
necrotic cell death, by antagonizing various 
factors that eventually lead to the failure of 
cellular metabolism. But after CNS trauma, 
necrosis is an early event, and the 
therapeutic window for these strategies is 
short. Recent experimental work 
substantiated the important role of 
apoptosis as a secondary injury mechanism. 
In contrast to necrosis, apoptosis is a more 
delayed process, that enreels for days, even 
weeks after the initial trauma, which is why 
modulating it is likely to be a more effective 
approach. 
Apoptotic inhibitors are currently in the 
experimental phase, but they are a dynamic 
and very promising research field. 
Calpain inhibitors  
Calpains are constitutively expressed 
intracellular, non-lysosomal cysteine 
proteases. They are classified as ubiquitous 
and tissue-specific. The ubiquitous 
isoforms, μ-calpains (or calpains I) and m-
calpains (or calpains II), are abundantly 
expressed in the central nervous system 
(CNS). Their activation requires the 
presence of Ca2+ (in micromolar 
concentrations for calpains I and in 
millimolar concentrations for calpains II) 
(73). 
 
 
 
Figure 3 Activation of calpains - within the calpains 
pathway of apoptosis (G. Onose et al. Integrative 
emphases on intimate, intrinsic propensity/ pathological 
processes – causes of self recovery limits and also, subtle 
related targets for neuroprotection/ pleiotropicity/ multimodal 
actions, by accessible therapeutic approaches - in spinal cord 
injuries. Journal of Medicine and Life,3(3): 262-74, 2010) 
 
Although various calpain substrates have 
been identified (cytoskeletal proteins, 
growth factor receptors, adhesion 
molecules, transcription-related proteins), 
the precise function of these enzymes in 
vivo is still poorly understood (111). The 
massive cellular Ca2+ influx associated 
with CNS injury inevitably activates 
calpains, which, in conjunction with 
caspases, promote irreversible damages to 
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key cellular structures that finally lead to 
apoptosis. 
The endogenous specific inhibitor of 
calpains is calpastatin (CAST), but 
overactivation of calpain may degrade 
calpastatin. A number of cell-permeable 
calpain inhibitors (e.g. epoxysuccinate 
derivatives, aldehydes, and alpha-keto 
carbonyl compounds) (71) have been 
synthesized and tested on animal models of 
TBI and other CNS injuries, and some of 
them showed important neuroprotective 
effects (47, 73). 
Caspase (cysteinyl aspartic acid-protease) 
inhibitors 
Based on their substrate specificity, there 
have been identified 14 mammalian 
caspases (110). These enzymes are 
translated as zymogen proforms and upon 
activation, caspases may cleave their own 
precursors or other procaspases, resulting in 
a caspase activation cascade (112). 
Caspases are involved in several 
interrelated apoptotic pathays, which are 
not yet completely understood. Caspase-3 
has received most of attention, since it 
appears to be the major effector in neuronal 
apoptosis. Initial strong evidence 
supporting the specific role for this protease 
came from studies on caspase-3 knock-out 
mice, in which brain development was 
severely altered (110). Later, in vivo and in 
vitro experiments with semispecific peptide 
caspase inhibitors (Z-DEVD-FMK, Z-
IETD-FMK, Z-LEHDFMK) (8) 
established the role of this protease in 
injury-induced neuronal loss (47). 
Cathepsin inhibitors  
Like calpains, cathepsins also belong to 
the papain superfamily of cystein proteases. 
Cathepsins are found predominantly in the 
lysosomes, but also in the cell nuclei and 
cytosol. These enzymes have also been 
implicated in neuronal injury, and 
inhibitors such as CA-074 and E-64c have 
been proven to significantly decrease 
neuronal death(113). 
PARP-1 [Poly(ADP-Ribose) Polymerase 
-1] inhibitors 
Recent research shows that while mild 
damages to DNA activate the repair 
mechanisms, severe insults induce PARP-1 
overactivation and cell death (11). 
PARP-1 is an abundant nuclear protein, 
functioning as a DNA damage-sensor and 
signaling molecule. Upon binding to DNA 
breaks, activated PARP-1 cleaves NAD+ 
into nicotinamide and ADP-ribose and 
polymerizes the latter into branched nucleic 
acid-like polymers, covalently attached to 
nuclear acceptor proteins. The negative 
charge of these covalently attached ADP-
ribose polymers severely alter the function 
of target proteins (such as histones, 
topoisomerases, DNA polymerases, DNA 
ligases, transcription factors and PARP-1 
itself) (11).  
Researchers tested a large number of 
PARP-1 inhibitors (nicotinamide, 3-
aminobenzamide, monoaryl amides, bi-, 
tri-, or tetracyclic lactams), most of them 
acting as competitive inhibitors that block 
the binding of NAD+ to the catalytic 
domain of the enzyme. Some benzamides 
have also been shown to inhibit the binding 
of PARP to DNA(104). Many of these 
compounds have been shown to protect 
neuronal tissue against various insults, in 
vitro and in vivo (91, 101). 
A recent study demonstrated that 
minocycline and other tetracycline 
derivatives, previously researched for their 
neuroprotective properties, also inhibit 
PARP-1 activity and reduce neuronal death 
(1). 
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Antioxidants 
Oxidative stress in one of the key 
mechanisms of secondary injury in CNS 
traumas and an attractive target for 
neuroprotection. The oxygen free radicals 
cause peroxidation of membrane 
phospholipids and oxidation of cellular 
proteins and nucleic acids, damaging both 
neurons and cerebral vasculature.  
Superoxide dismutase (SOD) 
SOD is a physiological antioxidant, an 
enzyme that reduces the superoxide anion 
concentration by dismutation to hydrogen 
peroxide, which is then converted to water.  
SOD has a very short half-life (of about 
5 minutes), which limits its clinical utility, 
but conjugation with polyethylene glycol 
(PEG) extends its half-life to approximately 
5 days (105). 
The polyethylene glycol-conjugated 
SOD (PEG-SOD, pegorgotein) proved to 
be safe in phase II clinical trials and seemed 
to improve the outcome of head-injured 
pacients (59). As a consequence, it 
underwent a phase III, multicentric, 
randomized, placebo-controlled trial. The 
study enrolled 463 patients with severe, 
closed head injury. The treated groups 
received a single intravenous dose of eithr 
10 000 U/kg, or 20 000 U/kg of 
pegorgotein. No significant difference in 
neurologic outcome or mortality was found 
at 3 or 6 months between the treated groups 
and the placebo group (114). 
New / experimental procedures 
Local hypothermia 
Hypothermia (the intentional reduction 
of core temperature below 36°C) is thought 
to protect the blood-brain barrier and 
prevent inflammation, the development of 
vasogenic edema and intracranial 
hypertension, while decreasing cerebral 
metabolic rate for oxygen and energy 
requirements (94, 106). Whole body 
hypothermia has been intensively studied as 
a neuroprotective intervention, especially in 
newborn. A number of clinical trials 
studied the effects of general hypothermia 
in ischemic stroke, neonatal hypoxic-
ischemic encephalopathy and ischemic 
stroke (42). Though experimental and 
clinical results showed that this procedure 
exerts some neuroprotective effects, the use 
of whole body cooling is hindered by 
serious complications (e.g. sedation, 
arrhythmia, coagulopathies, increased risk 
of infection, tremor, hypotension, 
hyperkalaemia) (79, 94). 
Local hypothermia is a newer and 
apparently safer intervention. Experiments 
showed that even profound local 
hypothermia does not damage cortical 
neurons (106). A phase III clinical trial is 
currently on going, to assess the feasibility 
and efficacy of discrete cerebral hypotermia 
in TBI (42). 
Hyperbaric oxygen therapy 
Oxygen is largely used as a therapeutic 
agent. Hyperbaric oxygen therapy consists 
in administering 100% oxigen at pressures 
higher than 1 atmosphere (0,1Mpa) using a 
small hyperbaric chamber or a mask (9). 
This procedures achieves hyperoxia, leading 
to an increase of the physically disolved 
blood oxygen, wich is proportional to the 
partial pressure of the oxygen in the 
ambient.  
Hyperoxia exerts a variety of beneficial 
effects: improvement of tissue oxygenation, 
decrease of inflammation, stimulation of 
tissue repair mechanisms, antibacterial 
effects and consequently it has a broad 
range of clinical applications, for conditions 
that involve ischemia, impairment of tissue 
repair, inflammation, infection. Hyperbaric 
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oxygen  is an an established therapy, 
approved in many countries for many 
indicatons such as: monoxide poisoning, 
decompression sickness, gas embolism, 
necrotizing soft tissue infections, diabetic 
wounds, osteoradionecrosis. (9). The main 
concern with the use of hyperbaric oxygen 
therapy is systemic vasoconstriction (9), but 
the extensive clinical experience with this 
procedure proved it’s safety if application 
parameters are rigourously controlled 
(duration, pressure). 
A consistent body of research exists for 
the use of this intervention in TBI and it 
has been suggested that, despite the cerebral 
vasoconstriction it produces, hyperoxia has 
many beneficial actions that may sum up to 
better rehabilitative outcomes: increasing 
the partial pressure of oxygen in brain 
tissue, restoring the mitochondrial redox 
potential (enhancing damaged 
mitochondrial recovery) (19, 76), 
decreasing intracranial pressure (9,77). A 
prospective, randomized clinical trial 
compared the effect of hyperbaric to 
normobaric hyperoxia when aplied to 
severe TBI patients within 24 hours of 
injury; while both procedures increased 
brain oxygenation and improved indices of 
oxidative metabolism (in comparison to the 
control group), only hyperbaric oxygen 
lowered intracranial pressure. However, 
these effects were transient, lasting only a 
few days after the intervention. No 
significant adverse reactions were recorded 
(77). 
A phase II clinical trial is presently on 
going to assess the feasibility of hyperbaric 
oxygen therapy in patients with chronic 
sequelae following brain injury (42). 
 
Conclusions 
In experimental conditions, various 
pharmachological agents lead to impressive 
reductions in the extent of brain damage 
and consequent significant neurological 
recovery after TBI, inciting high 
expectations of a clinical benefit.  
But to date, all the clinical trials failed to 
demonstrate a radical improvement with 
any of these agents. Furthermore, many of 
these substances (like many glutamate 
receptor antagonists) were found to have 
serious side effects. Yet, on one hand, 
compound products such as Cerebrolysin 
(more and more largely used and tested in 
standardized, multicentric clinical trials – 
including our involvement for one of them) 
and on the other, citicoline (which, as 
previously emphasized, is considered in in 
many countries a supplement – and 
therefore is easily accesible and very widely) 
seem to be in a recent prestigious review 
(40) the most efficient substances used in 
connection with neurorehabilitation 
practice. Novel achievements in 
neuroprotection are now expected from 
developing anti-apoptotic agents (such as 
caspase and/or calpain inhibitors), from 
more potent antioxidants, cholinergic 
agents, alpha blockers, from researching 
various physiologic substances, like 
protirelin, inosine, progesterone, and 
including from regenerative medicine and 
physiatric, assisstive technology/  
bioengineering advancements, all within 
multidisciplinary and intricate endeavours – 
on a still long and windy road. 
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